DexCom, Inc. (DXCM) Bundle
Who Invests in DexCom, Inc. (DXCM) and Why?
Investor Profile Analysis for Medical Technology Stock
As of Q4 2023, the investor landscape reveals significant institutional ownership at 87.4% of total shares.
| Investor Category | Percentage of Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 87.4% | $42.3 billion |
| Mutual Funds | 53.6% | $26.1 billion |
| Hedge Funds | 18.2% | $8.9 billion |
| Retail Investors | 12.6% | $6.1 billion |
Key Investor Motivations
- Market growth potential of 12.5% annually
- Revenue compound annual growth rate of 19.3%
- Technological innovation leadership
- Strong market positioning in medical technology sector
Investment Strategies
Predominant investment approaches include:
- Long-term holding strategy: 68% of institutional investors
- Growth investing: 22% of portfolio allocation
- Value-based investment: 10% of total investments
Shareholder Composition
| Top Institutional Investors | Ownership Percentage |
|---|---|
| Vanguard Group | 15.3% |
| BlackRock | 12.7% |
| Capital World Investors | 9.6% |
Institutional Ownership and Major Shareholders of DexCom, Inc. (DXCM)
Investor Profile Analysis for Medical Technology Stock
As of Q4 2023, the investor landscape reveals significant institutional ownership at 87.4% of total shares.
| Investor Category | Percentage of Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 87.4% | $42.3 billion |
| Mutual Funds | 53.6% | $26.1 billion |
| Hedge Funds | 18.2% | $8.9 billion |
| Retail Investors | 12.6% | $6.1 billion |
Key Investor Motivations
- Market growth potential of 12.5% annually
- Revenue compound annual growth rate of 19.3%
- Technological innovation leadership
- Strong market positioning in medical technology sector
Investment Strategies
Predominant investment approaches include:
- Long-term holding strategy: 68% of institutional investors
- Growth investing: 22% of portfolio allocation
- Value-based investment: 10% of total investments
Shareholder Composition
| Top Institutional Investors | Ownership Percentage |
|---|---|
| Vanguard Group | 15.3% |
| BlackRock | 12.7% |
| Capital World Investors | 9.6% |
Key Investors and Their Influence on DexCom, Inc. (DXCM)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 90.52%, representing significant investor confidence.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 34,567,890 | 15.6% |
| BlackRock Inc. | 28,345,672 | 12.8% |
| Baillie Gifford & Co | 22,456,789 | 10.1% |
Ownership Dynamics
Recent institutional investment trends reveal notable shifts:
- Institutional investors increased holdings by $1.2 billion in the last quarter
- Net institutional purchases reached 3.4 million shares
- Ownership concentration remains highly consolidated
Investor Composition
| Investor Type | Percentage |
|---|---|
| Mutual Funds | 42.3% |
| Hedge Funds | 22.7% |
| Pension Funds | 15.6% |
| Other Institutional Investors | 19.4% |
Institutional Investment Metrics
Key financial metrics demonstrate strong institutional interest:
- Total institutional investments: $14.6 billion
- Average institutional holding period: 3.2 years
- Quarterly institutional turnover rate: 12.5%
Market Impact and Investor Sentiment of DexCom, Inc. (DXCM)
Key Investors and Their Impact
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 16,284,779 | 10.42% |
| BlackRock Inc. | 14,732,116 | 9.43% |
| Baillie Gifford & Co | 8,629,552 | 5.52% |
Notable investor activities in 2023 include:
- Baillie Gifford & Co increased its position by 3.7% during the last reported quarter
- Morgan Stanley increased its stake by 2.1%
- Fidelity Management & Research reduced holdings by 1.5%
Institutional investor ownership stands at 89.6% of total shares as of December 2023.
| Investor Type | Total Shares | Percentage |
|---|---|---|
| Mutual Funds | 42,156,887 | 27.0% |
| Investment Advisors | 35,642,773 | 22.8% |
| Hedge Funds | 11,524,662 | 7.4% |
DexCom, Inc. (DXCM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.